Epigenetic silencing of cyclooxygenase-2 affects clinical...

Details Epigenetic silencing of cyclooxygenase-2 affects clinical... Epigenetic silencing of cyclooxygenase-2 affects clinical...

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01)

Patent

CA 2690879

The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen.

La présente invention concerne des procédés permettant d'utiliser le statut de méthylation de la région promoteur du gène COX-2 en tant que biomarqueur chez un patient souffrant d'un cancer gastrique afin d'établir un pronostic et un régime thérapeutique, ainsi que de surveiller le progrès d'un régime thérapeutique.

Affiliated with

Also associated with

Rating

Epigenetic silencing of cyclooxygenase-2 affects clinical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epigenetic silencing of cyclooxygenase-2 affects clinical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epigenetic silencing of cyclooxygenase-2 affects clinical... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1565208